NCT02528253: A reported trial by Pfizer
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02528253 |
|---|---|
| Title | A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 18, 2015 |
| Completion date | Oct. 17, 2017 |
| Required reporting date | Oct. 17, 2020, midnight |
| Actual reporting date | Dec. 19, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |